Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (927 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-05-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartcoronaryerlotinibcardiacartery
  Phrases that lowered it: mgsafety ofabnormalexaminationevaluate the
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 5.3% (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 115 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 18.4% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 263 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 77.7% (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Blinding: double (raises risk) · Design
• Drugs with FDA adverse-event history: 2 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma NCT01774344 · started 2013 · scored riskier than 42% of active trials completed
• Sorafenib Chemoembolization Evaluation Controlled Trial NCT01906216 · started 2013 · scored riskier than 70% of active trials completed
• Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP) NCT00892658 · started 2009 · scored riskier than 58% of active trials completed
• Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study NCT05117957 · started 2022 · scored riskier than 58% of active trials completed
• A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib NCT01140347 · started 2010 · scored riskier than 43% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.